Document Type : Original Research Article


1 Department of Chemistry, Ahmadu Bello University, Zaria, Nigeria

2 Department of Chemistry, Al-Qalam University, Katsina, Nigeria


Eight novel triphenylamine chalcones with different substitution patterns were successfully synthesized using the conventional Claisen-Schmidt condensation reaction in basic medium at room temperature, and purified by recrystallization method using ethanol, the percentage yield of the compounds were between 30 – 92 %. The synthesis of the target chalcones involves a nucleophilic enolate attack on the electrophilic carbonyl carbon of 4-(Diphenylamino) benzaldehyde resulting in the formation of a new carbon-carbon bond. The triphenylamine chalcones were characterized by means of FT-IR and NMR spectroscopic analyses. The antimicrobial screening against different pathogens revealed that, all synthesized compounds showed marked activity against the tested microbe. (E)-3-(4-(diphenylamino)phenyl)-1-(3'-nitrophenyl)prop-2-en-1-one (1b) showed the highest zone of inhibition against Aspergillus niger, measuring 30 mm. The minimum inhibitory concentration (MIC) results revealed that, (E)-1-(4'-bromophenyl)-3-(4-(diphenylamino)phenyl)prop-2-en-1-one (1a), (E)-3-(4-(diphenylamino)phenyl)-1-(3'-nitrophenyl)prop-2-en-1-one (1b), (E)-1-(4'-chlorophenyl)-3-(4-diphenylamino)phenyl)prop-2-en-1-one (1c), (E)-3-(4-diphenylamino)phenyl)-1-(4'-fluorophenyl)prop-2-en-1-one (1d) and (E)-4-(3-(diphenylamino)phenyl)-1-(4-fluorophenyl)-2-methylbut-3-en-1-one (2d) had the lowest MIC and inhibit Aspergillus niger growth at 12.5 µg/ml. All the synthesized compounds showed an MBC/MFC effect against Escherichia coli, Pseudomonas aeruginosa, Bacillus subtilis, Candida albicans and Aspergillus niger at 50 µg/ml.

Graphical Abstract

Syntheses, Characterization and Biological Evaluation of Some New (2E)-1-(4'-bromophenyl)-3-(4-(diphenylamino)phenyl)prop-2-en-1-one Chalcones and their analogues


  • The resurgence of several infections and the increasing resistance of pathogenic microbes to available chemotherapeutic agents are imperative issues in drug design and development,
  • Chalcones have been proved to be attractive moieties in drug discovery.
  • Eight novel triphenylamine chalcones with different substitution patterns were successfully synthesized via the conventional Claisen-Schmidt condensation reaction in an alkaline medium and purified by recrystallization method from ethanol.
  • The structures of the triphenylamine chalcones were successfully characterized and confirmed by FT-IR and NMR spectroscopic analyses.
  • The antimicrobial investigation revealed that (E)-3-(4-(diphenylamino)phenyl)-1-(3'-nitrophenyl)prop-2-en-1-one (1b) showed highest ZOI (30 mm), lowest MIC (12.5 µg/ml) and MBC/MFC (50 µg/ml) on Aspergillus niger.


Main Subjects

[1] A. Phrutıvorapongkul, V. Lıpıpun, N. Ruangrungsı, K. Kırtıkara, K. Nıshıkawa, S, Maruyama and T. Ishıkawa, Studies on the chemical constituents of stem bark of Millettialeucantha: isolation of new chalcones with cytotoxic, anti-herpes simplex virus and anti-inflammatory activities. Chemistry and Pharmaceutical Bulletin, 51 (2003) 187-190.
[2]             J.H. Cheng, C.F. Hung, S.C. Yang, J.P. Wang, S.J. Won and C.N. Lin, Synthesis and cytotoxic, anti-inflammatory, and anti-oxidant activities of 2, 5-dialkoxylchalcones as cancer chemopreventive agents. Bioorg. Medicinal Chemistry, 16 (2008) 7270-7276.
[3]             H. Rücker, N. Al-Rifai, A. Rascle, E. Gottfried, L. Brodziak-Jarosz, C. Gerhäuser, and S. Amslinger, Enhancing anti-inflammatory activity of chalcones by tuning the Michael acceptor site. Biomolecules Chemistry, 13 (2015) 3040–3047
[4]             A.P. Bonakdar, F. Vafaei, M. Farokhpour, M.N. Esfahani and A.R. Massah, Synthesis and anticancer activity assay of novel chalcone-sulfonamide derivatives. Iran Journal of Pharmaceutical Res, 16 (2017) 565–568.
[5]             P. Shukla, M. Satyanarayana, P.C. Verma, J. Tiwari, A.P. Dwivedi, R. Srivastava and R. Pratap, Chalcone-based aryloxypropanolamine as a potential antidiabetic and antidyslipidaemic agent. Curriculum of Science, 12 (2017) 1675–1689
[6]             A.M. Katsori and D. Hadjipavlou-Litina, Chalcones in cancer: understanding their role in terms of QSAR. Curriculumn of Medicinal Chemistry, 16 (2009) 1062-1081
[7]             G. Achanta, A. Modzelewska, L. Feng, S.R. Khan and A. Huang, Boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome. Molecular Pharmacology, 7 (2006) 426-433.
[8]             A. Modzelewska, C. Pettit, G. Achanta, N.E. Davidson, P. Huang and S.R. Khan, Anticancer activities of novel chalcone and bis-chalcone derivatives. Bioorganic Medicinal Chemistry, 14 (2006) 3491-3495.
[9]             S.K. Kumar, E. Hager, C. Pettit, H. Gurulingappa, N.E. Davidson and S.R. Khan, Design, synthesis, and evaluation of novel Boronic-chalcone derivatives as antitumor agents. Journal of Medicinal Chemistry, 46 (2003) 2813-2815
[10] K.L. Lahtchev, D.I. Batovska, S.P. Parushev, V.M. Ubiyvovk and  A.A. Sibirny, In vitro `antifungal evaluation and structure-activity relationships of a new series of chalcone derivatives and synthetic analogues, with inhibitory properties against polymers of the fungal cell wall. European Journal of Medicinal Chemistry, 43 (2008) 2220-2228.
[11] M. Sortino, P. Delgado, S. Juarez, J. Quiroga, R. Abonia, B. Insuasty S. Zacchino, In vitro
antifungal activity of new series of homoallylamines and related compounds with inhibitory properties of the synthesis of fungal cell wall polymers. Bioorg. Medicinal Chemistry, 11 (2007) 1531-1550.
 [12] S.N. Lopez, M.V. Castelli, S.A. Zacchino, J.N. Dominguez, G. Lobo, J. Charris and R.D. Enriz, In vitro antifungal evaluation and structure-activity relationships of a new series of chalcone derivatives and synthetic analogues, with inhibitory properties against polymers of the fungal cell wall. Bioorg. Medicinal Chemistry, 9 (2001) 1999-2013.
 [13] T.M. Osorio, F.D. Monache, L.D. Chiaradia, A. Mascarello, T.R. Stumpf, C.R. Zanetti, A.
Smânia, Antibacterial activity of chalcones, hydrazones and oxadiazoles against methicillin-resistant. Staphylococcus aureus. Bioorg. Medicinal Chemistry Letter, 22 (2012) 225 –230.
   [14] N. Selvakumar, G.S. Kumar, A.M. Azhagan, G.G. Rajulu, S. Sharma, M.S. Kumar, S. Trehan, Synthesis, SAR and antibacterial studies on novel chalcone oxazolidinone hybrids.       European Journal of Medicinal Chemistry, 42 (2007) 538-543.
[15] H.P. Avila, E.F. Smania, F.D. Monache and A. Smania, Structure-activity relationship of           antibacterial chalcones. Bioorg Medicinal Chemistry, 16 (2008) 9790-9794.
[16] S. Pradip, M. Khushboo, C. Anand, G. Devanshi, S. Sudha, K. Sweta and K. Meena,
Activity of newly synthesized chalcone derivatives against H1N1 virus supported by molecular docking and membrane interaction studies. Journal of Antivirous Antiretrovir, 8 (2016) 79–89.
[17] Z. Nowakowska, A review of antiinfective and anti-inflammatory chalcones. European    
     Journal of Medicinal Chemistry, 42 (2007) 125-137.
[18] D. Kozlowski, P. Trouillas, C. Calliste, P. Marsal, R. Lazzaroni and J.L. Duroux, Density   
functional theory study of the conformational, electronic and antioxidant properties of natural chalcones. Journal of Physics and Chemistry, 1 (2007) 1138-1145
[19] Z. Xu, S. Zhao, Z. Lv, L. Feng, Y. Wang, F. Zhang and J. Deng, Benzofuran derivatives and their anti-turbacular and anti-bacterial activities. European Journal of Medicinal Chemistry, 162 (2019) 266-276.
 [20] F. Herencia, M.P. Lopez-Garcıa, A. Ubeda and M.L. Ferrandiz, Nitric oxide-scavenging properties of some chalcone derivatives. Journal of Biology and Chemistry, 6 (2002) 242-246.
[21] P. Quintana-Espinoza, C. Yanez, C.A. Escobar, D. Sicker, R. Araya-Maturana and J.A. Squella, Electrochemical approach to the radical anion formation from 2’-hydroxy chalcone derivatives. Electroanal., 18 (2006) 521-525. 
[22] B.P. Bandgar, S.S. Jalde, L.K. Adsul, S.N. Shringare, S.V. Lonikar, R.N. Gacche and A.L. 
Shirfule, Synthesis of new olefin chalcone derivatives as antitumor, antioxidant and antimicrobial agents. Medicinal Chemistry Residence, 21 (2012) 4512–4522.
[23] G. Avila-Villarreal, O. Hernández-Abreu, S. Hidalgo-Figueroa, G. Navarrete-Vázquez, F. Escalante-Erosa, L.M. Pena-Rodríguez and S. Estrada-Soto, Antihypertensive and vasorelaxant effects of dihydrospinochalcone-A isolated from Lonchocarpus xuul Lundell by NO production: Computational and ex vivo approaches. Phytomedicine, 20 (2013) 1241–1246.
[24] M. Sangeetha, C.R. Reichal and N. Thirumoorthy, Synthesis and biological evaluation of some novel heterocyclic chalcone derivatives. World Journal of Pharmaceutical and Life Sciences, 3 (2017) 263-267.
[25] G. Romanelli, G. Pasquale, A. Sathicq, H. Thomas, J. Autino and P.V. Azquez, Synthesis and medicinal application of chalcones scaffolds. Journal of Molecular Catalyst A Chemistry, 3 (2011) 24-40.
[26] S. Eddarir,  N. Cotelle,  Y. Bakkour and C. Rolando, Tetrahedron Letter,  44 (2003) 53-59.
[27] M.J. Climent, A. Corma, S. Iborra and A. Velty, Synthesis of Chalcones: A Review. Journal of molecular Catalyst, 2 (2004) 474-500.
[28] P. Jaiswal, P. Dharam, B. Himangini A. Uma, Chalcone and their heterocyclic analogue. Journal of Chemical and Pharmaceutical Research, 10 (2018) 160-173
[29] Z. Hongtian , T. Lei, Z. Chenghong, W. Baochu, Y. Pingrong, H. Dian, Z. Lifang,  Z. Yang, Synthesis of Chalcone Derivatives: Inducing Apoptosis of HepG2 Cells via Regulating Reactive Oxygen Species and Mitochondrial Pathway, 2019.
[30] D. Karou, A. Savadogo, A. Canini, S. Yameogo, C. Montesano, J. Simpore, V. Colizzi, and A.S. Traore, Antibacterial activity of alkaloids from Sida acuta. Afr. J. Biotechnol., 5 (2006) 195-200.
 [31] L.L. Bruton, J.S. Lazo and K.L. Parker, The Pharmaceutical basis of therapeutics (Ed 11th) Mc Graw-Hill medical publishing division, New York, 2007.